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Formalin-fixed paraffin-embedded (FFPE) tissues are a real treasure for retrospective 
analysis considering the amount of samples present in hospital archives, combined with 
pathological, clinical and outcome information available for every sample. Although 
unlocking the proteome of these tissues is still a challenge, new approaches are being 
developed. In this review, we summarize the different mass spectrometry platforms that 
are used in human clinical studies to unravel the FFPE proteome. The different ways of 
extracting cross linked proteins and the analytical strategies are pointed out. Also, the 
pitfalls and challenges concerning the quality of FFPE proteomic approaches are depicted. 
We also evaluated the potential of these analytical methods for future clinical FFPE 

























In the post-genomic era, it has become clear that protein profile changes are important 
reflectors of biological and clinical phenomena. Furthermore, proteins are key effector 
molecules influencing pathological conditions. Mass spectrometry-based proteomics has 
therefore become an attractive technology to study disease-related protein differences. In 
disease related proteomics, the use of tissues is favorable over biological fluids, as 
investigating direct at the pathology site has several advantages, e.g. higher concentrations 
of disease-specific proteins. Although fresh or fresh frozen clinical specimens are ideal for 
proteomic analysis, the limited availability of these samples is a serious drawback. In 
recent years, it was suggested that formalin-fixed paraffin-embedded (FFPE) tissue might 
be a good alternative for frozen tissues (Nirmalan et al. 2008; Reimel et al. 2009; 
Klopfleisch et al. 2011).  
 
Formalin fixation followed by paraffin embedding is the most common procedure for long-
term preservation of clinical samples. Mostly, hundreds of formalin-fixed paraffin-
embedded diseased and paired healthy tissues are collected in hospital archives, as they 
are routinely prepared for pathological analysis. The by far most interesting issue of these 
FFPE specimens is that they hold pathological, clinical and outcome information inherently 
linked to every clinical sample. Also, large cohorts of samples might be available in a short 
period of time. Therefore, these samples are a real treasure for retrospective proteomic 
analysis, in order to elucidate pathological pathways or retrieve disease-associated 
biomarkers. However, the extensive formaldehyde-induced protein/DNA/RNA crosslinking 
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is a barrier for many analytical platforms and successful removal of these crosslinks is 
complicated.  
Today, several research groups try to unlock the proteome of FFPE tissues. In this review, 
we outline the use of FFPE samples in proteome analysis. We also describe the challenges 




2 Crosslinking and Protein extraction 
 
The fixation of clinical samples in formalin, followed by embedding in paraffin, is a 
worldwide known standard operating procedure used to perform histopathological 
examinations and to preserve clinical samples for a long time at room temperature. 
However, this processing of the tissue significantly modifies the proteins due to both 
fixation induced crosslinking events and exposure to heat and organic solvents (Ralton and 
Murray 2011). Typically, tissues are fixed for 24-48h in a 10% v/v solution of formalin (= 37-
40% w/w formaldehyde in water with 10% methanol as stabilizer) (Nirmalan et al. 2008). 
As formaldehyde is the smallest aldehyde, it can quickly penetrate tissues and fix them by 
crosslinking proteins, RNA and DNA. These crosslinks are preferentially formed at primary 
amino groups and side chains of amino acids such as arginine, tyrosine, histidine, 
asparagine, glutamine and tryptophan. More detailed information about the chemistry of 
crosslinking can be found in the article by Klockenbusch et al. 2012 (Klockenbusch et al. 
2012). Extracting proteins out of these crosslinked tissues requires robust methods to 
remove the crosslinks, but should not, on the other hand, produce changes itself. Until a 
decade ago, it was believed that the proteins in these samples were inaccessible for direct 
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mass spectrometric analysis. However, since the introduction of the heat-induced antigen 
retrieval technique, developed to increase the reactivity in immunohistochemical assays in 
FFPE tissue, better extraction of proteins has been achieved (Shi et al. 1991). Based on this 
antigen retrieval procedure, Ikeda and co-workers were the first to enhance the extraction 
of proteins from FFPE tissue by heating the sections in a buffer containing 2% SDS (Ikeda et 
al. 1998). From then on, the quality and quantity of proteins that could be extracted was 
improved using customized buffer compositions. Although the QProteome FFPE Tissue kit 
(Qiagen, Hilden, Germany) and Liquid tissue MS protein prep kit (Expression pathology Inc., 
Rockville, MD) are commercially available and solubilization and isolation of intact proteins 
is feasible, many research groups produce their own extraction buffer in order to achieve 
even better results. Importance of heat, detergent, protein denaturant and physical 
agitation for efficient protein extraction are common components in all protocols. An 




3 Proteome analysis using mass spectrometry  
 
Mass Spectrometry (MS) based applications make it possible to analyze complex protein 
samples and to identify and/or quantify hundreds of proteins in a high throughput manner. 
Because MS allows the analysis of hundreds of proteins within a single assay and without 
the need of prior knowledge of potential proteins of interest, it has a major advantage over 
classical immunohistological assays. Also, there is no need to purchase commercially 




In order to successfully analyze FFPE extracted proteins by mass spectrometry, reversal of 
these formalin-induced crosslinks is required and knowledge about the reaction products 
and the resulting modifications is needed. It is already known that the formation of 
modifications during fixation is influenced by several factors, including the rate of the 
crosslink reaction, the position and local environment of the amino acids, the pH of the 
reaction solvent as well as the components that are present and their concentrations 
(Metz et al. 2004). Several research groups tried to elucidate the reaction of formaldehyde 
with proteins and peptides (Metz et al. 2006; Metz et al. 2004; Toews et al. 2008). The 
reaction starts with the formation of methylol adducts (Δm= + 30) on primary amine 
groups. These adducts are followed by a partially dehydration which yields a labile Schiff 
base (Δm= +12), that will form crosslinks with other amino acids. Although expected, both 
modifications are not found in raw MS data. Their results do also show that the chemistry 
of formaldehyde crosslinking is considerably more complex, and the resulting mixture of 
products is far more heterogeneous than first presumed. Therefore, these authors 
presume that crosslinked products might be difficult to assess by mass spectrometry.  
 
However, besides the fact that some of these modifications are not yet elucidated, FFPE 
tissues are already used to perform proteomic analysis. Several research groups made the 
comparison between the proteome of fresh frozen material versus FFPE tissue, to evaluate 
the use of FFPE tissue as suitable sample source for proteomic analysis. These findings are 
nicely reviewed elsewhere (Tanca et al. 2012a). In short, an overlap of about 40% to 90% 
was found between the proteome profiles of fresh frozen versus FFPE tissue, depending on 
the analytical platform used. Also, the equivalence of the FFPE phosphoproteome and FFPE 
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N-glycome compared to fresh frozen tissue could be demonstrated using IMAC 
phosphopeptide enrichment in combination with LC-MS/MS (Ostasiewicz et al. 2010; 
Gamez-Pozo et al. 2011). 
The use of FFPE tissue as sample source in retrospective clinical studies is widely applied 
today. Many different analytical proteomic platforms were used to achieve the same goal: 
find protein profiles which differ between diverse clinical conditions. These analytical 
platforms can be subdivided in four major categories: Shotgun (LC-MS/MS) proteomics, 
MALDI Imaging, gelbased platforms and targeted analysis of proteins. An overview of 
clinical proteome studies using human FFPE tissue is summarized according to analytical 
platform in Table 2 (Fig.1). 
 
3.1 Shotgun (LC-MS/MS) proteomics 
 
For a couple of years now, shotgun proteomics is the method of choice for the analysis of 
complex samples. Here, enzyme-digested proteins are separated using liquid 
chromatography (LC) and analyzed by tandem mass spectrometry (MS/MS). This peptide-
centric gel-free analysis platform has the possibility to analyse samples in a high 
throughput manner and enables the identification and quantification of thousands of 
peptides in just a couple of hours.  
 
In the context of FFPE proteomics, the first shotgun experiments were performed in order 
to identify as much confident peptides/proteins as possible, without any quantification 
purposes. Palmer-Toy and colleagues pioneered in 2005 in Reverse Phase (RP) LC-MS/MS 
proteomics of FFPE tissue and could identify 123 proteins in FFPE material. To identify 
these proteins, they prespecified the standard modifications, methionine oxidation and 
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cysteine carbamidomethylation, but ignored other modifications induced by the 
crosslinking event. However, they tried to compensate this with an increased number of 
trypsin miscleavages and the use of the reversed database peptide strategy, i.e. translated 
open reading frames in reversed (‘decoy’) orientation, reducing false positive 
identifications (Palmer-Toy et al. 2005). Also in 2005, Prieto and colleagues identified 350 
proteins in colon FFPE tissue using RP LC-MS/MS and in house developed software (Prieto 
et al. 2005). To gain insights in the pathology of prostate cancer, Hwang et al. provided a 
global proteomic analysis using the direct tissue proteomics method, in which the whole 
tissue slice is used to extract proteins, further digested with trypsin and separated applying 
RP LC-MS/MS (Hwang et al. 2007). For the confident identification of proteins, they 
prespecified methionine oxidation and phosphorylation (STY) as possible modification in 
combination with the decoy database searching approach to minimize false positive 
identification. However, again no special settings were used to handle with the crosslinked 
protein products. Bagnato and colleagues also used the Direct Tissue Proteomics (DTP) 
method, but compared it with Laser Capture Microscopy (LCM), which can isolate specific 
areas or cell types in a FFPE tissue. They found 710 proteins in coronary vessels FFPE tissue 
using the DTP strategy, but only 225 proteins were identified with more than one peptide 
identification. Using LCM in combination with in solution digestion and LC-MS/MS on the 
other hand, resulted in 495 multihit protein identifications (Bagnato et al. 2007). Again, no 
special settings were proposed to deal with FFPE tissue.  
 
Crockett et al. downscaled the LC-system and used nano-RP-LC-MS/MS to achieve higher 
sensitivity. In their proof-of-principle experiment, they used the SUDHL-4 cell line, derived 
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from human transformed B-cell lymphomas, pelleted the cells, fixed and embedded them 
and performed a shotgun proteomic analysis. To digest the extracted FFPE proteins, they 
used both trypsin and glutamic C endopeptidase, ensuring that some crosslinked proteins, 
inaccessible for trypsin digestion, could be digested and thus identified. A result of 324 
unique protein identifications from 10 replicate runs was achieved by combining the 
identified proteins from trypsin digestion, glutamic C digestion and a combination of both 
enzymes. However, the authors did not specify any modifications using database search, 
probably explaining why the number of protein identifications is still limited (Crockett et al. 
2005). Cheung and colleagues identified 523 unique proteins in pancreatic cancer using 
tryptic digestion in combination with triplicate nano-RP-LC-MS/MS runs (Cheung et al. 
2008). Also here, no modifications were specified. Donadio and colleagues optimized 
extraction buffers containing high amounts of SDS for both gelbased and gelfree purposes 
and furthermore tried to use it for LC-MS/MS by combining ‘SDS out kit’ and TCA/Acetone 
precipitation. With this gelfree protocol, they were able to identify 163 confident proteins 
from adenoma parathyroid tissues using RP LC-MS/MS settings (Donadio et al. 2011). 
However, despite the effort they put in the efficient extraction of proteins, no solutions 
were proposed to deal with the protein crosslink problem for MS data analysis. 
 
Since the development of the multidimensional protein identification technology (MudPIT) 
in 1999 (Link et al. 1999; Washburn et al. 2001), where complex samples were first 
separated using strong cation exchange (SCX), and all the separate fractions are then 
analyzed using online reverse phase (RP) chromatography, the use of 2D-LC to elucidate 
complex proteomes has emerged exponentially. Also in the FFPE proteomics, 2D-LC was 
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used in several different setups. The use of an integrated capillary isoelectric focusing 
(CIEF) and nano-RP-LC-MS/MS system was used to identify over 1800 confident proteins in 
renal FFPE samples (Shi et al. 2006). Although the authors did not mention any 
prespecified modifications, the increased number of identification compared to prior 
proteome experiments is stunning and results from the combination of 2D separation and 
nano-LC systems. This 2D-LC combination was also used by Guo and co-workers, who 
splitted the FFPE protein sample into 19 CIEF fractions and resolved them further by nano-
RP-LC and nano-ESI-LTQ-MS/MS. Using this approach, they could identify 2,733 proteins in 
glioblastoma multiforme FFPE tissues (Guo et al. 2007). Concerning prespecified 
modifications, the authors made following settings: alkylated cysteine as fixed 
modifications and acetylation (N-terminus + lysine) and oxidized methionine as variable 
modifications. They also included the decoy strategy to outrule false positive 
identifications. 
The combination of 1D gel electrophoresis and LC-MS/MS is another 2D experimental 
setup which is used by Tanca and colleagues to reduce the complexity of the proteome of 
neuroendocrine archival tissue (Tanca et al. 2011a). They compared two different 
fractionation methods: excision of 13 visible protein bands vs slicing of the whole gel lane 
into 38 fractions. Whole gel lane fractionation yielded more protein identifications (153) 
compared to visible band excision (92). Again, crosslinked protein products are ignored in 
the database searching methods, although they mention the fact that the position on 1D 




In clinical FFPE proteomics however, most research groups perform proteome studies to 
find protein profiles which differ in abundance between diverse conditions. For 
quantification purposes in FFPE proteomics research, label-free approaches have become 
popular. In these label-free approaches, each sample is individually prepared and analyzed 
in an 1D or 2D LC-MS/MS setup. Furthermore, quantification can be achieved by protein 
abundance correlation through either mass spectrometric ion intensities of MS or MS/MS 
signals (peak intensity) or the number of MS/MS spectra per peptide and protein (spectral 
counting)(Li et al. 2012). This last method is more frequently been used in FFPE 
proteomics, as it suffers less from the peptide overlap of different fractions. Bateman and 
coworkers for example, used spectral counting to find differential protein profiles in breast 
cancer samples to indicate early-to-late stage progression as well as recurrence of the 
disease (Bateman et al. 2011). Also other research groups used FFPE proteomics in 
combination with spectral counting to elucidate protein expression changes involved in 
tumor progression. Patel and colleagues profiled the progression of head and neck cell 
squamous carcinoma at proteome level. In total, 391 proteins were identified in normal 
squamous epithelium, 866 in well differentiated epithelium, 729 in moderate 
differentiated and 676 in poorly differentiated epithelium (Patel et al. 2008). Also in renal 
cancer, spectral counting was used to characterize different stages using LC-MS/MS 
(Perroud et al. 2009). In the search for stage-related protein candidates in lung cancer, 
Kawamura used spectral counting and found more than 500 identified proteins, of which 
81 were correlated with stage Ia or IIIa (Kawamura et al. 2010). To understand the 
proteomic changes in melanoma progression and metastasis, Huang et al. used the label-
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free peak intensity approach and did find 120 proteins that were differentially expressed in 
metastasis compared to primary melanomas (Huang et al. 2009).  
 
Also for quantitation purposes, the addition of an orthogonal LC dimension will help to 
mine deeper into the FFPE proteome. Naidoo and co-workers for example, used spectral 
counting in combination with MudPIT separation to assess proteomic differences between 
primary pancreatic tumors and matched lymph node metastasis (Naidoo et al. 2012). From 
the 115 proteins that were differentially expressed, S100P and 14-3-3 sigma were further 
confirmed using immunohistochemistry (Naidoo et al. 2012). Negishi and co-workers used 
their own developed label free method called 2DICAL (2 Dimensional Image Converted 
Analysis of Liquid Chromatography) to find differentially expressed proteins in tongue 
cancer. They could collect 25,018 MS peaks and did find 72 peaks which were significantly 
differentially expressed between cancer and normal epithelia (Negishi et al. 2009). The 
research group of Mathias Mann used specialized MaxQuant software to perform label-
free quantitation for proteins extracted from both colon and breast archival tissues, using 
Filter aided sample preparation - Strong Anion Exchange (FASP-SAX) fractionation, 
followed by RP separation coupled to an Orbitrap mass spectrometer (Wisniewski et al. 
2011). Using the same strategy and multi-enzyme digestion, the research group revealed 
that identification of 10,000 proteins from human colon FFPE tissue is possible (Wisniewski 
et al. 2012).  
 
All these studies indicate that these label-free techniques have potential to elucidate 
biological questions regarding differential protein profiles using archival FFPE tissues. The 
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major advantage of this label-free technique is that no additional steps for labeling are 
needed and thus no extra costs are involved. Certainly in FFPE context, where additional 
labeling chemistry might complicate the results even more, label-free methods are 
popular. The major disadvantage however, is that run-to-run variation needs to be 
controlled to the most possible extend, which might be a challenge, even with state-of-the-
art instruments. Also, although a broad dynamic range is reached for peptide 
identification, a high amount of spectral counts is necessary to obtain reliable 
quantification results. Therefore, some authors opted to use enzymatic or chemical 
labeling strategies.  
 
Hood and co-workers pioneered in labeling-based methods on FFPE tissue using 
enzymatically facilitated 18O labeling to quantify tryptic peptides after separation using 
nano-RP-LC-MS/MS. They could identify 1,300 unique peptides from 702 proteins selected 
out of 200,000 cells of benign prostatic hypotrophy tissue and found 69 differentially 
expressed proteins between prostate cancer and benign prostatic hypertrophy (Hood et al. 
2005). Although identified and quantified, prostate specific antigen (PSA) could not make a 
distinction between these two prostate-specific diseases. The 18O proteolytic labeling 
strategy was also employed by Nazarian et al., to profile the FFPE proteome of brainstem 
glioma compared to normal tissue (Nazarian et al. 2008). In total, they could identify and 
quantify 188 proteins and found 54 up-regulated proteins, of which several were already 
linked to cancer. Although incubation of peptides with trypsin in 18O enriched water 
provides a straightforward way to label peptides, a major disadvantage of this technique is 
that the reproducibility is heavily dependent on many factors including labeling time, 
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temperature, amount and activity of the trypsin and also back reaction between 18O and 
16O is possible (Wu et al. 2012).  
 
For that reason, chemical labeling strategies e.g. Isobaric tags for relative and absolute 
quantification (iTRAQ) are also used. The major advantages using isobaric tags involve the 
possibility to multiplex up to 8 samples into one LC-MS/MS run thereby saving instrument 
time and reducing the run-to-run variation seen in label-free methods. Moreover, it has 
been shown that isobaric chemical labeling can provide more accurate and precise 
quantification of proteins compared to label-free methods (Li et al. 2012). A disadvantage, 
on the other hand, is that the labels are only integrated after protein reduction, alkylation 
and digestion, creating thus variability. In the context of FFPE proteomics, the labeling 
efficiency of crosslinked peptides is also major concern. Jain and co-authors though, 
demonstrated that the iTRAQ technology was able to quantify 114 FFPE extracted proteins, 
which could lead to discrimination between HIV(+) and HIV(-) patients (Jain et al. 2008). 
Xiao and co-workers used iTRAQ quantification in combination with MudPIT technology to 
perform a proteome analysis on nasopharyngeal carcinoma (Xiao et al. 2010). According to 
the author, a good iTRAQ labeling performance was achieved, despite the presence of 
crosslinked proteins. To elucidate the pathology of diabetic nephropathy, Nakatani et al. 
used iTRAQ and could find 55 proteins that were upregulated and 45 downregulated 
proteins in glomerular cross sections from diabetic patients with nephropathy. Most of 
them are linked to renal and urological disease (Nakatani et al. 2012). Again, no special 






3.2 Mass Spectrometry Imaging 
 
 
Mass spectrometry imaging (MSI) is a mass spectrometric technique that enables the 
visualization of proteins without losing spatial information. In proteomics applications 
mostly Matrix Assisted Laser Desorption Ionization (MALDI)-MSI is applied (Amstalden van 
Hove et al. 2010). In MALDI-MSI, matrix is first deposited on a thin tissue section, the 
sample surface is rastered according to a predefined rectangular X, Y grid and full mass 
spectra are acquired in each pixel where analytes are deserted upon laser irradiation. The 
intensity values of different ions can be plotted upon the initial raster, generating a spatial 
image (Walch et al. 2008; Cornett et al. 2007). Furthermore, the technique allows to map 
hundreds of proteins/peptides simultaneously in a thin tissue section with a spatial 
resolution of 50 µm (Minerva et al. 2012). A major advantage using imaging techniques is 
that no extensive extraction procedures, purifications and separations are conducted. Also, 
there is no need to develop specialized antibodies, which makes it an ideal approach for 
biomarker discovery. The nature of the proteins and their distribution in the tissues can be 
directly attributed to morphological or biochemical changes (Goodwin et al. 2008). 
Herefore, it is complementing classical immunohistological approaches, like 
immunohistochemistry and in situ hybridization, that require prior knowledge of the target 
proteins (Angel and Caprioli 2013). However, the MALDI-imaging method works best for 
small hydrophilic and abundant proteins but fails to detect a large number of proteins, 
even in fresh material. Also, absolute quantification of proteins using MSI is not possible 




The use of FFPE tissue slices as an alternative for fresh frozen material for MSI is known for 
several years now. In 2007, Lemaire and coworkers could show that direct tissue MSI of 
FFPE tissues stored less than 1 year was feasible for peptides smaller than 5 kDa using 2,4-
dinitrophenylhydrazine as matrix. To analyze the proteins in the FFPE sample, they 
implemented an enzymatic digestion protocol, as MSI imaging of FFPE tissues is mainly 
limited to peptide analysis, because chemical crosslinked proteins are difficult to assess 
with mass spectrometry (Lemaire et al. 2007). More recent reports illustrate that FFPE 
imaging of proteins/peptides by MSI is feasible by combining the antigen retrieval 
technique and in situ enzymatic digestion before matrix application (Gustafsson et al. 
2010; Djidja et al. 2009; Seeley and Caprioli 2011; McDonnell et al. 2012). 
 
The lab of Caprioli could show that the spatial expression of some proteins, including S100-
A9, differs between adenocarcinoma and squamous cell lung carcinoma by application of 
tissue microarrays (TMA) (Groseclose et al. 2008). In TMAs several tissue cores are placed 
into a single paraffin block, sectioned, and in this way analyzed simultaneously. TMAs have 
gained tremendous interest as these allow high throughput analysis from large clinical 
cohorts (Groseclose et al. 2008). In 2010, TMAs and MALDI MSI were applied to detect 
cancer specific or histological type-specific proteins using gastric cancer FFPE samples 
(Morita et al. 2010). Morgan and colleagues also combined TMA and MALDI MSI and found 
a peptide signature that could accurately distinguish malignant from normal renal tissue 
(Morgan et al. 2013). MALDI-MSI of FFPE tissues was also used to distinguish spitz nevus 
from spitzoid malignant melanoma. Five peptides were found to be differentially 
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expressed and could classify spitz nevus with 97% sensitivity and 90% specificity using a 
validation cohort of 59 samples (Lazova et al. 2012). 
 
3.3 Gelbased proteomics 
 
Although gelbased proteomics is still the only technique which can visualize thousands of 
proteins in one image, interest in the workhorse of proteomics has decreased. Also in 
FFPE-applied proteomics, the number of research articles is limited. In 2003, Ahram and 
colleagues showed that the application of 2D gels to ethanol-fixed paraffin embedded 
tissues was more successful than using tissues fixed with formaldehyde (Ahram et al. 
2003). The ethanol fixed protein spots in the gel were a bit fuzzy, but a good comparison 
with the frozen material was possible. The 2D gel separation of FFPE extracted proteins on 
the other hand, did not show any spot, only streaking and blurring. In 2009, Ono and co-
workers did use 2D DIGE to compare the FFPE proteome of uterine cervix squamous cell 
carcinoma and healthy tissues, but could only show a low-quality 2D map with smears 
(Ono et al. 2009). Donadio and colleagues applied 2D electrophoresis using FFPE material 
from patients with sporadic primary hyperparathyroidism and did only found a low quality 
pattern of 16 spots and smears (Donadio et al. 2011). Until now, the research groups of 
Alessandro Tanca and Maria Filippa Addis are the only one managing to successfully 
separate proteins extracted from FFPE tissues using 2D gel electrophoresis (Addis et al. 
2009; Tanca et al. 2011b; Tanca et al. 2012c). Although their patterns are more comparable 
with fresh frozen tissues than other research groups ever achieved, the quality of FFPE 2D 




3.4 Targeted proteomics 
 
 
Selected Reaction Monitoring (SRM), also called Multiple Reaction Monitoring (MRM), is a 
technology that also complements the shotgun proteomics strategy as it allows the 
quantification of a predefined set of proteins. In an SRM workflow, the mass spectrometer 
will first target a specific peptide of interest in a first stage followed by targeting one (SRM) 
or more (MRM) of its fragment ions in a second stage. The combination of the precursor 
ion and fragment ions allows to specifically target the protein of interest in different 
samples, as all other acquired signals can be ignored (Picotti and Aebersold 2012; Lange et 
al. 2008). 
 
The performance characteristics of FFPE extracted protein quantitation by MRM is 
assessed by Sprung and colleagues. Their results did show that, as expected, the formalin-
induced chemical modifications decrease the sensitivity of the MRM measurements, 
meaning that fewer targets will be available for quantification compared to fresh tissues. 
However, in their proof-of-concept experiment in which they quantified the HER2 receptor 
expression profiles in breast tumors, the assay sensitivity of FFPE extracted proteins and 
fresh frozen samples was comparable, when using unmodified peptides (Sprung et al. 
2012). Grüzel and co-workers also made use of MRM quantification in order to find pre-
eclampsia related calcyclin peptides in placental FFPE tissue. Their MRM assay 
demonstrated that in pre-eclamptic patients elevated levels of calcyclin is observed in 
placental trophoblas cells compared to normal trophoblast cells (Guzel et al. 2011). An 
MRM quantitative analysis for stage-related proteins upon non-metastatic lung 
adenocarcinoma was performed by Nishimura and colleagues. This study suggested that 
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napsin-A and anterior gradient protein 2 homolog (hAG-2) would be useful for determining 
stage IA or IIIA lung adenocarcinoma. Both proteins could also be related to metastasis 
(Nishimura et al. 2010). In the context of FFPE extracted proteins for MRM applications, 
the Absolute QUAntification (AQUA) technique is also introduced. In the AQUA workflow, a 
peptide containing a stable-isotope labeled amino acid is synthesized based on the 
sequence of the targeted peptide of interest. This synthesized ‘heavy’ peptide is then 
spiked into the complex proteome sample and used as internal standard for quantification 
(Ye et al. 2009). The research group of Han used the AQUA technique to quantify prostate 
specific antigen (PSA) in prostate FFPE tissues and did find a trend of increasing levels of 
PSA in more advancing tumors (Hwang et al. 2007). To quantify pyruvate kinase M2 in 
endometrial samples and to confirm overexpression in cancer, Desouza et al. used Tags for 
Relative and Absolute quantification (mTRAQ) (DeSouza et al. 2010). In mTRAQ, up to 
three non-isobaric labels can be used to label a known quantity of a synthetic peptide 
whose sequence is identical to the tryptic peptide of interest and on the other hand, the 
sample containing tryptic peptides. After mixing and LC separation, the labeled peptides 
provide unique MRM transitions, both in MS mode (three non-isobaric parent ions) and in 
MS/MS mode (non-isobaric sequence ions) (DeSouza et al. 2008). 
 
 
4 Pitfalls and challenges 
 
Although a vast archive of clinical samples is present, FFPE tissues have been considered as 
obstinate to proteomic analysis. The reason why molecular analysis of these tissues is 




The presence of protein/DNA/RNA crosslinks is one of the most important issues which 
hamper proteomic analysis. Extraction of proteins from archival FFPE tissues is mostly 
accompanied by a combination of exposure to organic solvents, heat and proteolysis. 
Although shown to be efficiently, it even might be the question whether all proteins stay 
soluble in this combination. Also, the reversal of crosslinks renders several by-products, 
inaccessible for mass spectrometric analysis and possibly disturbing high quality LC 
separations. However, it is also known that only a small percentage of formaldehyde-
reactive amino acids form irreversible chemical modifications. In vitro models do show that 
the crosslink event is more complicated than theoretically assumed, and thus more 
unspecified modifications will turn up. Also, predicted peptide modifications, like methylol 
derivatives, are often not detected in experimental data. In addition, modifications due to 
chemical crosslinking might hinder tryptic digestion in some extent.  
This will lead to a second major challenge: the confident identification of proteins. Not only 
will unknown and unexpected modifications on (tryptic) peptides lead to a decreased 
protein and proteome coverage, also biases exist compared to fresh material in identified 
basic proteins and in the lysine/arginine ratio of identified proteins, as basic amino acids, 
and in particular lysine, are known to be involved in the crosslinking process (Tanca et al. 
2012a). Therefore, new bio-informatic approaches are needed to unlock the full FFPE 
proteome. The development of new algorithmic data-analysis software for LC-MS/MS data 




A third challenge is related to working with human tissues. It is already known that the 
variability between human samples is partly due to genetic diversity of humans, different 
environments, but also differences like age, gender and race that need to be controlled 
whenever one wants to perform proteomic profiling studies. Also, some ethical issues 
need to be considered, such as permissions that must be obtained from the patient before 
using the clinical sample for scientific purposes. This might not be a problem for samples 
gathered these days, but must also be present for FFPE samples that are already stored for 
over 10 years. 
 
Finally, several other, more technical factors determine the variability of FFPE proteome 
data. One of the major parameters that should be controlled is the time between the 
resection of the tissue and the fixation in formalin. Ideally, samples should be fixed 
immediately and completely from the living state. In animal models, this can be achieved 
using in vivo perfusion. In humans however, surgically removement is the only option, and 
anoxic periods due to anesthesia and surgical clamps can influence the expression patterns 
of proteins. These factors cannot be strictly controlled because they impact patient care, 
but could, on the other hand, be recorded in detail (Hewitt et al. 2008). Also the way of 
conservation of the tissue between resection and fixation (either dry or bading in a 
solution) can have implications and should be standardized.  
Another source of variability (and probably the easiest to control) is the fixation procedure. 
Three aspects are important during this protocol: the thickness of the tissue, the volume of 
the fixative and the fixation time. Unsuccessful optimization of these 3 elements results in 
under- or overfixation of the clinical samples, resulting in higher variation between 
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different specimens. Through the large diversity of size of resected specimens, fixation 
procedures might be difficult to standardize. Therefore, we suggest that larger specimens 
should be sectioned as soon as possible after their resection and the volume of the fixative 
is adapted to the size of the specimen, starting from a minimum formalin:tissue ratio is 
10:1. Concerning different fixation times, Tanca and co-workers made an evaluation of the 
efficiency of protein extraction and the quality of the obtained quantitative data. Their 
results show that successful identification of peptides decreases, as the fixation time 
increases (Tanca et al. 2012b). Unfortunally, it is common practice to fix specimens 
overnight or even over the weekend. Failure to standardize these steps will thus pose 
problems to the researchers working with the material.  
 
The archival time is also an important parameter that can introduce variability in datasets, 
as it influence the retrieval of proteins over time (Balgley et al. 2009). On top, differences 
in storage conditions e.g. temperature, humidity,… will also have an effect on the variation 
of the FFPE proteome. For data interpretation, the way of isolation of the tissue e.g. 
cutting cylindrical section, working with tissue slices or laser microdissected cells, will also 
influence the data. Overcoming all these technical issues and accomplish the goal of 
standardization is thus a major challenge. 
 
 
5 Future perspectives 
 
Recent advances in the field of FFPE proteomics demonstrate that unlocking the FFPE 
proteome might have major potential for retrospective and translational biomarker 
research. Unfortunately, current practices lack the required standardization. Therefore, 
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the use of fresh tissue remains the gold standard. To establish the use of FFPE material as 
primary tissue source for proteome studies, more investigations are needed to reduce the 
numerous variables and to achieve the many challenges. In the first place, protocol 
refinement is needed to manage the confounding FFPE data analysis which arises from 
different fixation times, storage periods, incomplete crosslink reversal etc. Therefore, more 
standardization in procedures of fixation and storage are needed to reduce biases and to 
maximize the dependability of the obtained proteomic results. These standard operation 
procedures should be systematically used in every hospital with an FFPE archive, which 
should create the possibility to perform multicentric proteomic studies. We also 
recommend obtaining as much information as possible regarding the surgery parameters, 
fixation times etc., which can only improve the quality and reproducibility of the scientific 
research. Also, existence of measures to assess the sample quality of archival tissues, both 
at molecular and morphological level, is critical and should reduce the variability in 
degradation effects between samples. Finally, the unraveling of all the peptide 
modifications induced by formalin crosslinking by means of bioinformatics and 
understanding the full process of crosslinking, might lead the FFPE proteome research 
towards complete acceptance. This translational (biomarker) research strategy depends 
thus on the interdisciplinary contributions of clinicians, scientists and biostatisticians.  
 
When evaluating different analytical platforms used in proteomics today, LC-MS/MS will 
probably have the most potential to unlock the FFPE proteome because of its capability to 
identify thousands of proteins in just a couple of hours. However, obtaining such results is 
only possible when new developments in the interpretation of FFPE raw data files succeed. 
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Also the combination of LC-MS/MS and MALDI-MSI might have opportunities for future 
clinical research, but with limitations concerning the mass range of proteins. This setup is a 
powerful tool because detecting differences in cells with specific spatial coordinates, 
combined with the identification of these specific candidates by LC-MS/MS make it 
possible to merge biomarker discovery and histopathology. Regarding targeted analysis, 
only non-modified peptides are applicable for high quality absolute quantification, making 
the development of MRM methods even more difficult than it is these days using fresh 
material. 
 
In conclusion, while considerable progress has been achieved, analysis of FFPE tissue 
proteome is still a major challenge. Using FFPE tissue in future proteome biomarker studies 
has potential, if more standardized methods will be applied and appropriate data-analysis 





















Table 1 : Compositions of different protein extraction buffers. 
 
 
No. Type Treatment Buffer composition Temperature (°C) Time (min) Agitation Reference
1 4x 8µm slices Sonication 2% SDS, 100mM ammonium bicarbonate, 20 mM DTT, pH 8,5 70 60 No Palmer-Toy,2005
2 Needle microdissection Paraffin removal by SubX Liquid tissue MS protein prep kit 95 90 Yes Prierto,2005
3 1 slice NA NDME-PE  (non-destructive molecule extraction) 100 30 No Chu,2005
4 1 tissue ffpe block NA  RIPA buffer / / No Crockett,2005
5 slices Sonication 40mM Tris-HCl, 6 M guanidine-HCl, 65mM DTT, pH 8,2 100 30 No Jiang, 2007
6 Laser microdissection NA 8 M urea ,20 mM Tris-HCl at pH 8.0 / / No Guo, 2007
7 Needle microdissection NA Qproteome FFPE kit 100+80 20+120 No Becker, 2007
8 5µm slices NA 30% ACN,  100mM NH4HCO3 100 10 NA Bagnato, 2007
9 Macrodissection NA 30% ACN,  100mM NH4HCO3 95 + 65 30+ 180 No Nazarian, 2008
10 3x 10µlm slices NA 100mM Tris-HCl pH 6,8, 20% v/v glycerol, 2% w/v SDS, 4% v/v beta-mercaptoethanol 105 20 No Nirmalan,2008
11 1x 60µm slices Sonication 50% 100mM ammonium bicarbonate, 50% Trifluoroethanol 80 + 60 120 + 60 No Sprung, 2009
12 50mg tissue, sl iced in 1-3mm thick Sonication 50% phosphate buffer, 50% Trifluoroethanol 60 120 No Tian,2009
13 5µm slices blender + sonication  100mM DTT, 100mM Tris-HCl pH 8,0 , 4% SDS 99 60 Yes Ostasiewicz, 2009
14 Macrodissection NA 2% SDS, 200mM DTT, 20mM Tris-HCl, 1% octylglucoside, 200mM glycine 100+ 80 20+120 Yes Azimzadeh, 2010
15 4x 7µm slices NA 20mM Tris-HCl pH 7, 2% SDS, 100 + 60 20 + 120 No Xiao, 2010
16 6x 10µm slices Elevanted pressure 50mM Tris-HCl pH 8, 2% SDS 100 + 80 30 + 120 No Fowler, 2010
17 3x 10µm slices NA 0,2 % rapigest in 50 mM ammonium bicarbonate 105 + 70 20 + 120 No Nirmalan, 2011
18 10µm slices NA 2% SDS, 200mM DTT, 20mM Tris-HCl 100+80 20+120 No Tanca, 2011
19 Laser capture microdissection NA 0,1M Tris-HCl, pH 8,0; 0,1M DTT, 0,5% (w/v) polyethylene glycol, 4% SDS 99 60 Yes Wisniewski, 2011
20 3x 5µm slices Homogenized using mixer high pH AgR buffer, pH 9.9; 1% NaN, 1% SDS, 10% glycerol and protease inhibitor 115 15 No Xie, 2011
21 Needle microdissection Sonication 62.5 mM Tris-HCl pH 6.8, 4% w/v SDS, 10% v/v glycerol, 100 mM DTT 105 45 No Craven, 2012
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Reference Clinical tissue # samples # proteins identified Analytical platform Separation Quantification
Shotgun
1 Craven, 2012 Kidney 16 2516 § LC-MS/MS ; LTQ RP-C18 Spectral counting
2 Naidoo, 2012 Pancreas 55 1504 LC-MS/MS ; LTQ SCX + RP-C18 Spectral counting
3 Nakatani, 2012 Kidney 20 170 LC-MS/MS ; Q-TOF NA iTRAQ
4 Wisnewski, 2012 Colon NA 9502 LC-MS/MS; Q exactive MED-FASP-SAX + RP-C18 Label-free, MaxQuant
5 Bateman, 2011 Breast 25 9437 * LC-MS/MS ; LTQ RP-C18 Spectral counting
6 Donadio, 2011 Parathyroid tissue 5 163 LC-MS/MS; LTQ Orbitrap XL RP-C18 None
7 Tanca, 2011 Lung 6 666 GeLC-MS/MS ; Q-TOF RP-C18 Spectral counting
8 Wisnewski, 2011 Colon NA 4419 LC-MS/MS; LTQ Orbitrap XL FASP-SAX + RP-C18 Label-free, MaxQuant
9 Kawamura, 2010 Lung 13 649 LC-MS/MS ; LTQ RP-C18 Spectral counting
10 Rezaul, 2010 Melanoma 1 tissue block 935 LC-MS/MS ; LTQ NA None
11 Xiao, 2010 Pharynx 40 730 LC-MS/MS; Q-TOF SCX + RP-C18 iTRAQ
12 Huang, 2009 Melanoma 24 555 LC-MS/MS ; LTQ RP-C18 Chromatographic peak intensity
13 Negishi, 2009 Tongue 20 25018 peaks ** LC-MS/MS ; Q-TOF 2DICAL 2DICAL
14 Nazarian, 2008 Brainstem 2 188 LC-MS/MS ; LTQ RP-C18 Isotope labeling
15 Perroud, 2009 Kidney 50 777 LC-MS/MS ; LTQ RP-C18 Spectral counting
16 Cheung, 2008 Pancreas 1 tissue block 523 LC-MS/MS ; LTQ RP-C18 None
17 Jain, 2008 Oral HPV lesions 10 114 LC-MS/MS ; MALDI RP-C18 iTRAQ
18 Patel, 2008 Head and neck 16 391, 866, 729, 676  *** LC-MS/MS ;LTQ RP-C18 Spectral counting
19 Ronci, 2008 Breast NA 70, 22, 59 **** LC-MS/MS ; Q-TOF RP-C18 None
20 Bagnato, 2007 Coronary vessels 35 710 LC-MS/MS ; LTQ RP-C18 Spectral counting
21 Guo, 2007 Glioblastoma 1 tissue block 2733 LC-MS/MS ; LTQ RP-C18 None
22 Shi, 2006 Kidney 4 1830 LC-MS/MS ; LTQ CIEF + RP-C18 None
23 Crockett, 2005 Lymphoma 1 tissue block 324 LC-MS/MS ; LCQ RP-C18 None
24 Hood, 2005 Prostate 2 1858 LC-MS/MS ; LTQ or LIT-FT-ICR RP-C18 Isotope labeling
25 Palmer-Toy,2005 Ear 1 123 LC-MS/MS ; LCQ Deca XP plus RP-C19 None
26 Prieto, 2005 Colon 1 350 LC-MS/MS ; LTQ RP-C18 None
MS Imaging
27 Lazova, 2012 Melanoma 114 5 differential peptides Maldi-MSI None None
28 Morgan, 2012 Kidney 70 de signature of 7 and 12 pe Maldi-MSI; Autoflex Speed None None
29 Morita, 2009 Stomach 9 4 cancer specific peptides Maldi-MSI; Qstar XL None None
30 Groseclose, 2008 Lung 50+10 50 Maldi-MSI None None
Gelbased
31 Tanca, 2012 Stomach + Lung NA NA Gelbased 2D gel 2D DIGE
32 Ono, 2009 Cervix 21 9 Gelbased+ LC-MS/MS: LCQ 2D gel 2D DIGE
Targetted
33 Sprung, 2012 Kidney, breast NA 1982 protein groups LC-MS/MS ; LTQ XL RP-C18 MRM
34 Gamez-Pozo, 2011 Lung + kidney 3+3 49 phospho + 154/42 phos  LC-MS/MS ; LTQ-Orbitrap XL IMAC + RP-C18 Phospho + MRM
35 Güzel, 2011 Placenta 10 141 LC-MS/MS ; QTRAP RP-C18 MRM
36 DeSouza, 2010 Endometrium 25 17 targeted proteins LC-MS/MS ; QTRAP RP-C18 MRM (mTRAQ)
37 Nishimura, 2010 Lung 27 NA LC-MS/MS ; QTRAP RP-C18 MRM
38 Hwang, 2007 Prostate 30 428 LC-MS/MS ; LTQ RP-C18 MRM (AQUA)
§ Total number of unique proteins in all  samples
* Sum of proteins after triplicate injections of 25 samples
** Only number of peaks described
*** Number of unique proteins per category
**** Number of unique proteins per protocol
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